Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy

Study Identifier
M02-570
CT.gov Identifier
NCT00646178
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Rheumatoid Arthritis
  • Psoriatic Arthritis (PsA)
    • Study Drug
  • adalimumab
  • placebo for adalimumab
    • Phase
    CSR.ORG
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - Moderate to severe PsA - Inadequate response to DMARD therapy - Corticosteroid stable dose <=10 mg QD - DMARDs must have been taken for 3 months and stable dose for 4 weeks - MTX maximum dose = <=30 mg/week - Active chronic plaque PS or documented history of chronic plaque PS
    Exclusion Criteria:
    - No other active skin disease

    Protocol Summary

    Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to

    Severely Active Psoriatic Arthritis Subjects with Inadequate Response to Disease Modifying

    anti-Rheumatic Drug Therapy

    Study Locations

    No locations found.